$AVXL News
Last published 1w ago
- 1w agoAVXLAnavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of DirectorsGlobeNewswireNEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for central
- 1w agoAVXLKirby McInerney LLP Alerts Investors Who Acquired Anavex Life Sciences Corp. AVXL Securities Between November 26, 2025 and August 28, 2026 of Pending LawsuitGlobeNewswireNEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL) investors of the November 30, 2026 deadline to seek the role
- 3w agoNTHINBIXACADAVXL+1Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar MarketGlobeNewswireNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For
- 3w agoAVXLAnavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical StudiesGlobeNewswireNEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous
- 3w agoAVXLAnavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X SyndromeGlobeNewswireAnavex now has open INDs in all three core indications: Alzheimer's disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and pharmacokinetics of blarcamesine oral
- 4w agoAVXLAVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 – Contact Kirby McInerney LLP to Discuss Your RightsBusiness WireIf you have suffered a loss on your Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com,
- 1mo agoAVXLSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXLPR NewswireThe Red Flags: What Insiders Allegedly Knew Before Shareholders Did. Anavex now says its Board reviews and executive certifications could operate on incomplete information, and it has told investors to rely only on its
- 1mo agoAVXLAVXL INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of Anavex Life Sciences Corp. ShareholdersGlobeNewswireNEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL) securities to contact Lauren
- 1mo agoAVXLPVG Asset Management Announces Plan for First 100 Days at Anavex Life SciencesGlobeNewswireCENTENNIAL, Colo., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of 337,663 shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the
- 1mo agoAVXLGlass Lewis Recommends Anavex Stockholders Vote the GOLD Universal Proxy Card, Citing “Functionally Inert Stewardship” in Support of PVG Asset Management’s Call for ChangeGlobeNewswire-- Proxy advisor recommends voting "FOR" two of PVG’s director nominees and "AGAINST" two incumbent director nominees including the board’s current chair on the GOLD Universal Proxy Card – -- PVG
- 1mo agoAVXLPVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price UnderperformanceGlobeNewswire-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board’s nominees – -- It’s too little, too late after a few months of the incumbent
- 1mo agoAVXLLeading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director NomineesGlobeNewswireISS Recognizes There is No Case for Change Anavex Urges Stockholders to Follow ISS’ Recommendation and Vote "FOR" ALL Six Director Nominees on the WHITE Proxy Card Today NEW YORK, Sept. 14, 2026 (GLOBE
- 2mo agoAVXLPVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy CampaignGlobeNewswireCENTENNIAL, Colo., Sept. 10, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ:AVXL) ("Anavex" or the "Company"), today announced
- 2mo agoAVXLANAVEX LIFE SCIENCES CORP. BUSINESS UPDATE - ANAVEX LIFE SCIENCES CORPEarnings Call TranscriptsWelcome to the Anovex Life Sciences Corp Business Update Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followe
- 2mo agoAVXLPVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)GlobeNewswireCENTENNIAL, Colo., Sept. 09, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corp. ("PVG"), a stockholder of Anavex Life Sciences Corp. (NASDAQ:AVXL, Anavex", or the ", Company", )), believes the
- 2mo agoAVXLAnavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ETGlobeNewswireNEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments
- 2mo agoAVXLAnavex Life Sciences Regains Compliance with Nasdaq Periodic Filing RequirementGlobeNewswireNEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments
- 2mo agoAVXLPVG Asset Management Corporation Files Definitive Proxy Statement and Launches Shareholder Website in Connection with Anavex Life Sciences Corp.’s 2026 Annual MeetingGlobeNewswireCENTENNIAL, Colo., Sept. 01, 2026 (GLOBE NEWSWIRE) -- PVG Asset Management Corporation ("PVG"), together with the other participants named below, has filed a definitive proxy statement on Schedule 14A (the
- 2mo agoAVXLAnavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business UpdateGlobeNewswireClinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett
- 2mo agoAVXLAnavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director NomineesGlobeNewswireLaunches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp.
- 3mo agoAVXLAnavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for StockholdersGlobeNewswireFiles Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote "FOR" All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan and
- 3mo agoAVXLAnavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value CreationGlobeNewswireNominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with
- 3mo agoAVXLAnavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireNEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous
- 5mo agoAVXLAnavex Life Sciences Receives Expected Nasdaq Delinquency NotificationGlobeNewswireNEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central
- 6mo agoAVXLAnavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive OfficerGlobeNewswireNEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's
- 7mo agoAVXLAnavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's DiseaseGlobeNewswireFindings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and
- 7mo agoAVXLAnavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireNEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 7mo agoAVXLAnavex Life Sciences Provides Comprehensive Regulatory UpdateGlobeNewswireDialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease Additional data submitted to the U.S. FDA with the objective to discuss
- 7mo agoAVXLAnavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's DiseaseGlobeNewswireNEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 7mo agoAVXLAnavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's DiseaseGlobeNewswireNew data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1
- 8mo agoAVXLAnavex Life Sciences to Present at the Citizens Life Sciences ConferenceGlobeNewswireNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 8mo agoAVXLAnavex Life Sciences to Present at the 46th TD Cowen Annual Health Care ConferenceGlobeNewswireNEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 8mo agoAVXLAnavex Life Sciences Appoints Seasoned Healthcare Leader to Board of DirectorsGlobeNewswireNEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 9mo agoAVXLAnavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business UpdateGlobeNewswireCompany to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company
- 9mo agoAVXLAnavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026GlobeNewswireNEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 10mo agoAVXLAnavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's DiseaseGlobeNewswireNEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European
- 10mo agoAVXLAnavex Life Sciences Appoints Senior Vice President Global Head of NeurologyGlobeNewswireNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 10mo agoAVXLAnavex Life Sciences Submitted Request for EMA to Re-Examine Its OpinionGlobeNewswireNEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 11mo agoAVXLAnavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's DiseaseGlobeNewswireNEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 11mo agoAVXLAnavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswireNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 11mo agoAVXLAnavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business UpdateGlobeNewswireCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company
- 11mo agoAVXLAnavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare ConferenceGlobeNewswireNEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 11mo agoAVXLAnavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025GlobeNewswireNEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 12mo agoAVXLAnavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's DiseaseGlobeNewswireCompany plans to request re-examination after CHMP opinion feedback following its oral explanation FDA advises Company to meet and discuss Company's Alzheimer's Disease clinical trial results NEW YORK, Nov. 14,
- 1y agoAVXLAnavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control GroupGlobeNewswireADAS-Cog13 difference −12.78 (P < 0.0001) with oral blarcamesine treatment compared to ADNI control group at Week 144 77.4 Weeks (17.8 Months) ‘time saved' with oral blarcamesine compared to ADNI Restoring impaired
- 1y agoAVXLAnavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care'GlobeNewswireNEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for
- 1y agoAVXLAnavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 ProgramGlobeNewswireANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current
- 1y agoAVXLAnavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaGlobeNewswireANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025
- 1y agoAVXLAnavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease TrialGlobeNewswirePublication title: "Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer's Disease Patients"
- 1y agoAVXLAnavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease TrialGlobeNewswireNew clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's disease Cognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine